1
|
Kearns ML, Reynolds CM. The impact of non-nutritive sweeteners on fertility, maternal and child health outcomes: a review of human and animal studies. Proc Nutr Soc 2024:1-13. [PMID: 38433591 DOI: 10.1017/s0029665124000168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/05/2024]
Abstract
There is significant evidence that an unhealthy diet greatly increases the risk of complications during pregnancy and predisposes offspring to metabolic dysfunction and obesity. While fat intake is typically associated with the onset of obesity and its comorbidities, there is increasing evidence linking sugar, particularly high fructose corn syrup, to the global rise in obesity rates. Furthermore, the detrimental effects of added sugar intake during pregnancy on mother and child have been clearly outlined. Guidelines advising pregnant women to avoid food and beverages with high fat and sugar have led to an increase in consumption of 'diet' or 'light' options. Examination of some human birth cohort studies shows that heavy consumption (at least one beverage a day) of non-nutritive sweetener (NNS) containing beverages has been associated with increased risk of preterm birth and increased weight/BMI in male offspring independent of maternal weight, which appears to be offset by breastfeeding for 6 months. Rodent models have shown that NNS exposure during pregnancy can impact maternal metabolic health, adipose tissue function, gut microbiome profiles and taste preference. However, the mechanisms underlying these effects are multifaceted and further research, particularly in a translational setting is required to fully understand the effects of NNS on maternal and infant health during pregnancy. Therefore, this review examines maternal sweetener intakes and their influence on fertility, maternal health outcomes and offspring outcomes in human cohort studies and rodent models.
Collapse
Affiliation(s)
- Michelle L Kearns
- School of Public Health, Physiotherapy and Sports Science/Conway Institute/Institute of Food and Health/Diabetes Complications Research Centre, University College Dublin (UCD), Belfield, Dublin, Ireland
| | - Clare M Reynolds
- School of Public Health, Physiotherapy and Sports Science/Conway Institute/Institute of Food and Health/Diabetes Complications Research Centre, University College Dublin (UCD), Belfield, Dublin, Ireland
| |
Collapse
|
2
|
Basson AR, Rodriguez-Palacios A, Cominelli F. Artificial Sweeteners: History and New Concepts on Inflammation. Front Nutr 2021; 8:746247. [PMID: 34631773 PMCID: PMC8497813 DOI: 10.3389/fnut.2021.746247] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2021] [Accepted: 08/23/2021] [Indexed: 12/12/2022] Open
Abstract
Since the introduction of artificial sweeteners (AS) to the North American market in the 1950s, a growing number of epidemiological and animal studies have suggested that AS may induce changes in gut bacteria and gut wall immune reactivity, which could negatively affect individuals with or susceptible to chronic inflammatory conditions such as inflammatory bowel disease (IBD), a disorder that has been growing exponentially in westernized countries. This review summarizes the history of current FDA-approved AS and their chemical composition, metabolism, and bacterial utilization, and provides a scoping overview of the disease mechanisms associated with the induction or prevention of inflammation in IBD. We provide a general outlook on areas that have been both largely and scarcely studied, emerging concepts using silica, and describe the effects of AS on acute and chronic forms of intestinal inflammation.
Collapse
Affiliation(s)
- Abigail Raffner Basson
- Division of Gastroenterology and Liver Diseases, Case Western Reserve University School of Medicine, Cleveland, OH, United States
- Digestive Health Research Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, United States
| | - Alexander Rodriguez-Palacios
- Division of Gastroenterology and Liver Diseases, Case Western Reserve University School of Medicine, Cleveland, OH, United States
- Digestive Health Research Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, United States
- Mouse Models, Silvio O'Conte Cleveland Digestive Diseases Research Core Center, Cleveland, OH, United States
- Germ-Free and Gut Microbiome Core, Digestive Health Research Institute, Case Western Reserve University, Cleveland, OH, United States
| | - Fabio Cominelli
- Division of Gastroenterology and Liver Diseases, Case Western Reserve University School of Medicine, Cleveland, OH, United States
- Digestive Health Research Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, United States
- Mouse Models, Silvio O'Conte Cleveland Digestive Diseases Research Core Center, Cleveland, OH, United States
- Germ-Free and Gut Microbiome Core, Digestive Health Research Institute, Case Western Reserve University, Cleveland, OH, United States
| |
Collapse
|
3
|
Lee CH, Yun W, Lee JH, Kwak WG, Oh HJ, An JS, Liu SD, Cho JH. Effects of artificial sweeteners on feed palatability and performance in weaned pigs. CANADIAN JOURNAL OF ANIMAL SCIENCE 2019. [DOI: 10.1139/cjas-2018-0143] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
In experiment 1, a total of 30 weaning pigs were allotted to three dietary treatments to check the palatability of the dietary feed. Diet treatments were as follows: reference diets = basal diets + 0.05% saccharin (50% Saccharin-natrium), TRT1 = 0.03% saccharin–neotame mix (50% Saccharine-natrium + 2% Neotame), TRT2 = 0.02% neotame (10% Neotame), and TRT3 = 0.02% saccharin–neotame mix (10% Saccharine-natrium + 10% Neotame). TRT2 group was significantly higher than other treatments in palatability (P < 0.05). In experiment 2, a total of 52 weaning pigs were allotted to four dietary treatments. In the average daily gain and average daily feed intake over 1 wk, the TRT2 group was significantly higher than the TRT1 and TRT3 groups (P < 0.05). The concentration of triglyceride in the blood was highest in the TRT1 treated group and the lowest in the TRT2 group (P < 0.05). The Lactobacillus was significantly higher in the TRT2 and TRT3 treatments compared with 0.05% saccharin (50% Saccharine-natrium) (P < 0.05). There was no significant difference in the number of Escherichia coli (P < 0.05). In conclusion, diets supplemented with neotame could improve palatability, and artificial sweeteners can affect nutrient digestibility, blood characteristic, and fecal microbiota.
Collapse
Affiliation(s)
- Chang Hee Lee
- Division of Food and Animal Sciences, Chungbuk National University, Cheongju 28644, South Korea
- Division of Food and Animal Sciences, Chungbuk National University, Cheongju 28644, South Korea
| | - Won Yun
- Division of Food and Animal Sciences, Chungbuk National University, Cheongju 28644, South Korea
- Division of Food and Animal Sciences, Chungbuk National University, Cheongju 28644, South Korea
| | - Ji Hwan Lee
- Division of Food and Animal Sciences, Chungbuk National University, Cheongju 28644, South Korea
- Division of Food and Animal Sciences, Chungbuk National University, Cheongju 28644, South Korea
| | - Woo Gi Kwak
- Division of Food and Animal Sciences, Chungbuk National University, Cheongju 28644, South Korea
- Division of Food and Animal Sciences, Chungbuk National University, Cheongju 28644, South Korea
| | - Han Jin Oh
- Division of Food and Animal Sciences, Chungbuk National University, Cheongju 28644, South Korea
- Division of Food and Animal Sciences, Chungbuk National University, Cheongju 28644, South Korea
| | - Ji Seon An
- Division of Food and Animal Sciences, Chungbuk National University, Cheongju 28644, South Korea
- Division of Food and Animal Sciences, Chungbuk National University, Cheongju 28644, South Korea
| | - Shu Dong Liu
- Division of Food and Animal Sciences, Chungbuk National University, Cheongju 28644, South Korea
- Division of Food and Animal Sciences, Chungbuk National University, Cheongju 28644, South Korea
| | - Jin Ho Cho
- Division of Food and Animal Sciences, Chungbuk National University, Cheongju 28644, South Korea
- Division of Food and Animal Sciences, Chungbuk National University, Cheongju 28644, South Korea
| |
Collapse
|
4
|
Effects of the Artificial Sweetener Neotame on the Gut Microbiome and Fecal Metabolites in Mice. Molecules 2018; 23:molecules23020367. [PMID: 29425148 PMCID: PMC6017827 DOI: 10.3390/molecules23020367] [Citation(s) in RCA: 52] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2017] [Revised: 01/28/2018] [Accepted: 01/30/2018] [Indexed: 12/22/2022] Open
Abstract
Although artificial sweeteners are widely used in food industry, their effects on human health remain a controversy. It is known that the gut microbiota plays a key role in human metabolism and recent studies indicated that some artificial sweeteners such as saccharin could perturb gut microbiome and further affect host health, such as inducing glucose intolerance. Neotame is a relatively new low-caloric and high-intensity artificial sweetener, approved by FDA in 2002. However, the specific effects of neotame on gut bacteria are still unknown. In this study, we combined high-throughput sequencing and gas chromatography-mass spectrometry (GC-MS) metabolomics to investigate the effects of neotame on the gut microbiome and fecal metabolite profiles of CD-1 mice. We found that a four-week neotame consumption reduced the alpha-diversity and altered the beta-diversity of the gut microbiome. Firmicutes was largely decreased while Bacteroidetes was significantly increased. The Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) analysis also indicated that the control mice and neotame-treated mice have different metabolic patterns and some key genes such as butyrate synthetic genes were decreased. Moreover, neotame consumption also changed the fecal metabolite profiles. Dramatically, the concentrations of multiple fatty acids, lipids as well as cholesterol in the feces of neotame-treated mice were consistently higher than controls. Other metabolites, such as malic acid and glyceric acid, however, were largely decreased. In conclusion, our study first explored the specific effects of neotame on mouse gut microbiota and the results may improve our understanding of the interaction between gut microbiome and neotame and how this interaction could influence the normal metabolism of host bodies.
Collapse
|
5
|
Critical review of the current literature on the safety of sucralose. Food Chem Toxicol 2017; 106:324-355. [DOI: 10.1016/j.fct.2017.05.047] [Citation(s) in RCA: 52] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2017] [Revised: 05/06/2017] [Accepted: 05/22/2017] [Indexed: 01/24/2023]
|
6
|
Berry C, Brusick D, Cohen SM, Hardisty JF, Grotz VL, Williams GM. Sucralose Non-Carcinogenicity: A Review of the Scientific and Regulatory Rationale. Nutr Cancer 2016; 68:1247-1261. [PMID: 27652616 PMCID: PMC5152540 DOI: 10.1080/01635581.2016.1224366] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2015] [Accepted: 06/20/2016] [Indexed: 12/20/2022]
Abstract
Regulatory authorities worldwide have found the nonnutritive sweetener, sucralose, to be noncarcinogenic, based on a range of studies. A review of these and other studies found through a comprehensive search of electronic databases, using appropriate key terms, was conducted and results of that review are reported here. An overview of the types of studies relied upon by regulatory agencies to assess carcinogenicity potential is also provided as context. Physiochemical and pharmacokinetic/toxicokinetic studies confirm stability under conditions of use and reveal no metabolites of carcinogenic potential. In vitro and in vivo assays reveal no confirmed genotoxic activity. Long-term carcinogenicity studies in animal models provide no evidence of carcinogenic potential for sucralose. In studies in healthy adults, sucralose was well-tolerated and without evidence of toxicity or other changes that might suggest a potential for carcinogenic effects. In summary, sucralose does not demonstrate carcinogenic activity even when exposure levels are several orders of magnitude greater than the range of anticipated daily ingestion levels.
Collapse
Affiliation(s)
- Colin Berry
- Emeritus Professor of Pathology, Queen Mary University of London, London, UK
| | | | - Samuel M. Cohen
- Department of Pathology and Microbiology, Havlik-Wall Professor of Oncology, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Jerry F. Hardisty
- Experimental Pathology Laboratories, Inc., Durham, North Carolina, USA
| | - V. Lee Grotz
- Director and R&D Fellow, Medical Affairs, Johnson & Johnson Consumer Inc., Fort Washington, PA, USA
| | - Gary M. Williams
- Department of Pathology, New York Medical College, Valhalla, New York, USA
| |
Collapse
|
7
|
Freitas MLF, Dutra MBDL, Bolini HMA. Sensory profile and acceptability for pitanga (Eugenia uniflora L.) nectar with different sweeteners. FOOD SCI TECHNOL INT 2016; 22:720-731. [DOI: 10.1177/1082013215607077] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2015] [Accepted: 08/24/2015] [Indexed: 12/17/2022]
Abstract
The objective of this study was to evaluate the sensory properties and acceptability of pitanga nectar samples prepared with sucrose and different sweeteners (sucralose, aspartame, stevia with 40% rebaudioside A, stevia with 95% rebaudioside A, neotame, and a 2:1 cyclamate/saccharin blend). A total of 13 assessors participated in a quantitative descriptive analysis and evaluated the samples in relation to the descriptor terms. The acceptability test was carried out by 120 fruit juice consumers. The results of the quantitative descriptive analysis of pitanga nectar showed that samples prepared with sucralose, aspartame, and the 2:1 cyclamate/saccharin blend had sensory profiles similar to that of the sample prepared with sucrose. Consumers' most accepted samples were prepared with sucrose, sucralose, aspartame, and neotame. The sweeteners that have the greatest potential to replace sucrose in pitanga nectar are sucralose and aspartame.
Collapse
Affiliation(s)
- Mírian Luisa Faria Freitas
- Department of Food Engineering and Technology, State University of São Paulo, São José do Rio Preto, São Paulo, Brazil
| | - Mariana Borges de Lima Dutra
- National Institute of Education, Science and Technology of the South of Minas Gerais State, Inconfidentes, Minas Gerais, Brazil
| | | |
Collapse
|
8
|
Zhu L, Wang G, Dong B, Peng C, Tian Y, Gong L. Effects of sweetener neotame on diet preference, performance and hematological and biochemical parameters of weaned piglets. Anim Feed Sci Technol 2016. [DOI: 10.1016/j.anifeedsci.2016.02.013] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
9
|
Rumelhard M, Hosako H, Eurlings IMJ, Westerink WMA, Staska LM, van de Wiel JAG, La Marta J. Safety evaluation of rebaudioside A produced by fermentation. Food Chem Toxicol 2016; 89:73-84. [PMID: 26776281 DOI: 10.1016/j.fct.2016.01.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2015] [Revised: 12/17/2015] [Accepted: 01/13/2016] [Indexed: 11/19/2022]
Abstract
The safety of rebaudioside A, produced fermentatively by Yarrowia lipolytica encoding the Stevia rebaudiana metabolic pathway (fermentative Reb A), is based on several elements: first, the safety of steviol glycosides has been extensively evaluated and an acceptable daily intake has been defined; second, the use of Y. lipolytica, an avirulent yeast naturally found in foods and used for multiple applications; and third the high purity of fermentative Reb A and its compliance with internationally defined specifications. A bacterial reverse mutation assay and an in vitro micronucleus test conducted with fermentative Reb A provide evidence for its absence of mutagenicity, clastogenicity and aneugenicity. The oral administration of fermentative Reb A to Sprague-Dawley rats for at least 91 days did not lead to any adverse effects at consumption levels up to 2057 mg/kg bw/day for males and 2023 mg/kg bw/day for females, which were concluded to be the No Observed Adverse Effect Levels. The results were consistent with outcomes of previous studies conducted with plant-derived rebaudioside A, suggesting similar safety profiles for fermentative and plant-derived rebaudioside A. The results of the toxicity studies reported here support the safety of rebaudioside A produced fermentatively from Y. lipolytica, as a general purpose sweetener.
Collapse
Affiliation(s)
- Mélina Rumelhard
- DSM Food Specialties B.V., Alexander Fleminglaan 1, 2613 AX, Delft, The Netherlands.
| | - Hiromi Hosako
- WIL Research Laboratories LLC, 1407 George Rd., Ashland, OH, 44805, USA.
| | - Irene M J Eurlings
- WIL Research Europe B.V., Hambakenwetering 7, 5231 DD, 's-Hertogenbosch, The Netherlands.
| | - Walter M A Westerink
- WIL Research Europe B.V., Hambakenwetering 7, 5231 DD, 's-Hertogenbosch, The Netherlands.
| | - Lauren M Staska
- WIL Research Laboratories LLC, 310 Millstone Drive, Hillsborough, NC, 27278, USA.
| | | | - James La Marta
- DSM Nutritional Products, 45 Waterview Boulevard, Parsippany, NJ, 07054-1298, USA.
| |
Collapse
|
10
|
Brathwaite WA, Crincoli CM, Eapen AK, Rihner MO, Nikiforov AI, Picut CA. A two-year dietary carcinogenicity study of (2R,4R)-monatin salt in mice. Food Chem Toxicol 2016; 91:191-201. [PMID: 26747975 DOI: 10.1016/j.fct.2015.12.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2015] [Revised: 12/19/2015] [Accepted: 12/22/2015] [Indexed: 10/22/2022]
Abstract
Groups of Crl:CD-1 (ICR) mice (60/group/sex) were fed 0 (2 control groups), 5000, 20,000, or 40,000 ppm of enzymatically sourced (2R,4R)-monatin salt ("R,R-monatin") in the diet for up to two years. There were no adverse effects on survival, incidence of palpable masses and tumors, feed consumption, hematology or serum chemistry parameters, organ weights, or ophthalmic, macroscopic, and microscopic examinations. The only notable effect was statistically significantly lower mean body weights and body weight gains in all treated groups, which generally occurred throughout the study and were most likely a result of caloric dilution of the test diets and not considered adverse. There were no test article-related changes in the incidence or occurrence of neoplastic diseases in mice on this study. The no-observed-effect-level (NOEL) for carcinogenicity of R,R-monatin fed to mice for 24 months was 40,000 ppm, the highest dietary concentration tested, which was equivalent to approximately 6502 and 7996 mg/kg bw/day in males and females, respectively.
Collapse
Affiliation(s)
| | | | - Alex K Eapen
- Cargill, Incorporated, 15407 McGinty Rd West, Wayzata, MN, 55391, USA.
| | - Marisa O Rihner
- Toxicology Regulatory Services, 2365 Hunters Way, Charlottesville, VA 22911, USA.
| | - Andrey I Nikiforov
- Toxicology Regulatory Services, 2365 Hunters Way, Charlottesville, VA 22911, USA.
| | | |
Collapse
|
11
|
Brathwaite WA, Crincoli CM, Eapen AK, Rihner MO, Nikiforov AI, Remick AK. A combined dietary chronic toxicity and two-year carcinogenicity study of (2R,4R)-monatin salt in Sprague-Dawley rats. Food Chem Toxicol 2016; 91:202-16. [PMID: 26747978 DOI: 10.1016/j.fct.2015.12.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2015] [Revised: 12/22/2015] [Accepted: 12/24/2015] [Indexed: 11/16/2022]
Abstract
In a combined chronic toxicity/carcinogenicity study, groups of Crl:CD(SD) rats were fed 0 (2 control groups), 5000, 20,000, or 40,000 ppm (2R,4R)-monatin salt (hereafter "R,R-monatin") in the diet for up to one year in the chronic toxicity phase and up to two years in the carcinogenicity phase. There were no adverse effects on survival, incidence of palpable masses, neoplasms, organ weights, or ophthalmic examinations. The only notable effect was statistically significantly lower mean body weights and body weight gains in all treated groups generally throughout the study, which were most likely a result of caloric dilution of the test diets. Effects of long-term R,R-monatin ingestion by rats were predominantly focused on the urinary system (i.e., clinical pathology alterations indicative of electrolyte and pH imbalances, increased incidence of renal calculi, mineralization and bone hyperostosis, and increased severity of chronic progressive nephropathy). The no-observed-adverse-effect level (NOAEL) for R,R-monatin from the chronic toxicity phase was 20,000 ppm (equivalent to an exposure level of 1080 mg/kg bw/day for males and 1425 mg/kg/day for females) and from the carcinogenicity phase was 5000 ppm (equivalent to an exposure level of 238 and 302 mg/kg bw/day for males and females, respectively).
Collapse
Affiliation(s)
| | | | - Alex K Eapen
- Cargill, Incorporated, 15407 McGinty Rd West, Wayzata, MN 55391, USA.
| | - Marisa O Rihner
- Toxicology Regulatory Services, 2365 Hunters Way, Charlottesville, VA 22911, USA.
| | - Andrey I Nikiforov
- Toxicology Regulatory Services, 2365 Hunters Way, Charlottesville, VA 22911, USA.
| | - Amera K Remick
- WIL Research, 310 Millstone Drive, Hillsborough, NC 27278, USA.
| |
Collapse
|
12
|
|
13
|
de Souza VR, Pereira PAP, Pinheiro ACM, Bolini HMA, Borges SV, Queiroz F. Analysis of various sweeteners in low-sugar mixed fruit jam: equivalent sweetness, time-intensity analysis and acceptance test. Int J Food Sci Technol 2013. [DOI: 10.1111/ijfs.12123] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Vanessa R. de Souza
- Food Science Department; Federal University of Lavras Câmpus Universitário; Postcode 3037 CEP 37200-000; Lavras/MG; Brazil
| | - Patrícia A. P. Pereira
- Food Science Department; Federal University of Lavras Câmpus Universitário; Postcode 3037 CEP 37200-000; Lavras/MG; Brazil
| | - Ana Carla M. Pinheiro
- Food Science Department; Federal University of Lavras Câmpus Universitário; Postcode 3037 CEP 37200-000; Lavras/MG; Brazil
| | - Helena M. A. Bolini
- Food and Nutrition Department; Faculty of Food Engineering; University of Campinas; Câmpus Universitario Zeferino Vaz - Cidade Universitaria; CEP 13083-970; Campinas/SP; Brazil
| | - Soraia V. Borges
- Food Science Department; Federal University of Lavras Câmpus Universitário; Postcode 3037 CEP 37200-000; Lavras/MG; Brazil
| | - Fabiana Queiroz
- Food Science Department; Federal University of Lavras Câmpus Universitário; Postcode 3037 CEP 37200-000; Lavras/MG; Brazil
| |
Collapse
|
14
|
Otabe A, Fujieda T, Masuyama T. Chronic toxicity and carcinogenicity of N-[N-[3-(3-hydroxy-4-methoxyphenyl) propyl]-α-aspartyl]-L-phenylalanine 1-methyl ester, monohydrate (advantame) in the rat. Food Chem Toxicol 2012; 49 Suppl 1:S35-48. [PMID: 22036026 DOI: 10.1016/j.fct.2011.06.040] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
Abstract
Groups of 55 male and 55 female Han Wistar rats were administered advantame (98.9-99.8% purity) in the diet at concentrations of 0, 2000, 10,000, or 50,000 ppm for 104 weeks, following parental exposure to the same levels from prior to mating and throughout gestation. Additional groups of 20 rats/sex and 10 rats/sex were dosed for a period of 52 weeks and constituted the toxicity and reversibility phases of the study. Achieved doses of advantame over the carcinogenicity study were 0, 97, 488, and 2621 mg/kg body weight/day in males and 0, 125, 630, and 3454 mg/kg body weight/day in females, respectively. A high incidence of a pale and swollen anus and changes in fecal composition were observed in the high-dose groups. There was no effect of treatment on mortality. Body weight gain in the high-dose males (50,000 ppm) was slightly reduced compared to controls after 52 and 104 weeks of treatment; the decrease was not considered to be of toxicological significance, but due to the non-nutritive nature of the high dietary concentration of advantame. During the toxicity phase, food conversion efficiency was slightly decreased in both sexes, at the 50,000 ppm dose level. Given the non-nutritive content of the diet, this finding was not considered biologically significant. There were no relationships between treatment and the results of hematological or urinalysis investigations. Clinical chemistry evaluations showed consistently lower plasma urea concentrations in both sexes treated at 50,000 ppm, which was reversed during the 6-week recovery phase following 52 weeks of treatment, indicating a lack of permanent effects. Terminal investigations at both the 52 and 104-week revealed a number of intergroup differences in absolute and/or relative organ weights; however, the differences did not show dose-response relationships, were minor in nature, and/or occurred only in one sex, and were not associated with any pathological findings, and they were considered not to be treatment-related. Evaluation of the histopathology of the carcinogenicity phase animals revealed an increased incidence of pancreatic islet cell carcinomas in males (incidence rates of 0/55, 1/55, 2/55, and 3/55 in the 0, 2000, 10,000, or 50,000 ppm groups, respectively) and of mammary gland adenomas in the high-dose females (incidence rates of 0 in the control through 10,000 ppm dose groups and 4/41 in the 50,000 ppm dose group). The incidence rates of these tumors did not attain statistical significance and/or remained within background historical control values, and they were considered to be unrelated to advantame treatment. The no-observed-adverse-effect level was considered to be 50,000 ppm in the diet, the highest concentration tested, equivalent to 2621 and 3454 mg/kg body weight/day in males and females, respectively. Advantame was concluded to be without carcinogenic activity.
Collapse
Affiliation(s)
- A Otabe
- Ajinomoto Co., Inc., 15-1 Kyobashi 1-Chome, Chuo-ku, Tokyo 104-8315, Japan.
| | | | | |
Collapse
|
15
|
Abstract
Advantame is an N-substituted (aspartic acid portion) derivative of aspartame that is similar in structure to neotame, another N-substituted aspartame. An extensive series of studies, were conducted on advantame to define the pharmacokinetics and metabolism in various species, subchronic and chronic toxicity in the rat and dog, carcinogenicity in the rat and mouse, genotoxicity, reproductive, and developmental toxicity, and human tolerability studies. The results of these studies, presented in overview in the present publication, and in greater detail in the accompanying publications, show that advantame is well tolerated by both animals and humans and does not possess systemic toxicity. The metabolic data demonstrate that the animal species used in the toxicity testing are relevant to the evaluation of human safety. The no-observed-adverse-effect levels (NOAELs) identified in the animal studies in which advantame was administered in the diet were generally the highest doses tested. Under the anticipated conditions of use, the predicted intakes of advantame are about 20,000- to 70,000-fold lower than the identified animal study NOAEL values. The results of the animal toxicology and human trial data support the safety of use of advantame in food.
Collapse
|
16
|
Hlywka J, Brathwaite WA, Rihner MO, Nikiforov AI, Eapen AK. A 90-day oral (dietary) toxicity study of the 2R,4R-isomer of monatin salt in Sprague-Dawley rats. Food Chem Toxicol 2011; 49:3249-57. [PMID: 21925562 DOI: 10.1016/j.fct.2011.09.004] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2011] [Revised: 08/31/2011] [Accepted: 09/01/2011] [Indexed: 10/17/2022]
Abstract
The root bark of Sclerochitin ilicifolius contains an intensely sweet substance analytically identified as isomers of 2-hydroxy-2-(indol-3-ylmethyl)-4-aminoglutaric acid and generically coined "monatin." Groups of male and female Crl:CD(SD) rats were fed 0 (control), 5000, 10,000, 20,000 or 35,000 ppm R,R-monatin salt in the diet for 90 days. There were no toxicologically relevant clinical or histopathological findings in any of the test article-treated groups. Significantly lower cumulative body weight gains were noted in the 35,000 ppm group. Mean body weights in the 35,000 ppm group males and females were 7% and 12% lower, respectively, than the control group at study week 13. In the absence of other observations associated with systemic toxicity and lower food consumption, the magnitude of the body weight difference in the 35,000 ppm group females relative to the control group exceeded 10%, which indicated attainment of a maximum tolerated dose (MTD) level. Based on the results of this study, and conservatively assuming the body weight observations at the MTD to be indicative of an adverse effect, the dietary no-observed-adverse-effect level (NOAEL) of R,R-monatin salt for 90 days was 20,000 ppm in female rats (approximately 1544 mg/kg bw/day) and 35,000 ppm in male rats (approximately 2368 mg/kg bw/day).
Collapse
Affiliation(s)
- J Hlywka
- Cargill, Inc.,15407 McGinty Road West, Wayzata, MN 55391, USA.
| | | | | | | | | |
Collapse
|
17
|
Safety evaluation of an enzymatically-synthesized glycogen (ESG). Regul Toxicol Pharmacol 2010; 57:210-9. [PMID: 20197075 DOI: 10.1016/j.yrtph.2010.02.009] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2009] [Revised: 02/03/2010] [Accepted: 02/24/2010] [Indexed: 11/21/2022]
Abstract
An enzymatically-synthesized glycogen (ESG), intended for use as a food ingredient, was investigated for potential toxicity. ESG is synthesized in vitro from short-chain amylose by the co-operative action of branching enzyme and amylomaltase. In an acute toxicity study, oral administration of ESG to Sprague-Dawley rats at a dose of 2000 mg/kg body weight did not result in any signs of toxicity. ESG did not exhibit mutagenic activity in an in vitro bacterial reverse mutation assay. In a subchronic toxicity study, increased cecal weights noted in the mid- (10%) and high-dose (30%) animals are common findings in rodents fed excess amounts of carbohydrates that increase osmotic value of the cecal contents, and thus were considered a physiological rather than toxicological response. The hematological and histopathological effects observed in the high-dose groups were of no toxicological concern as they were secondary to the physiological responses resulting from the high carbohydrate levels in the test diets. The no-observed-adverse-effect level for ESG in rats was therefore established to be 30% in the diet (equivalent to approximately 18 and 21 g/kg body weight/day for male and female rats, respectively). These results support the safety of ESG as a food ingredient for human consumption.
Collapse
|
18
|
Carakostas M, Curry L, Boileau A, Brusick D. Overview: The history, technical function and safety of rebaudioside A, a naturally occurring steviol glycoside, for use in food and beverages. Food Chem Toxicol 2008; 46 Suppl 7:S1-S10. [DOI: 10.1016/j.fct.2008.05.003] [Citation(s) in RCA: 171] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2008] [Accepted: 05/06/2008] [Indexed: 11/24/2022]
|
19
|
Subchronic toxicity of rebaudioside A. Food Chem Toxicol 2008; 46 Suppl 7:S11-20. [DOI: 10.1016/j.fct.2008.04.042] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2007] [Accepted: 04/28/2008] [Indexed: 11/17/2022]
|
20
|
Neotame as a sweetener and flavour enhancer - Scientific Opinion of the Panel on Food Additives, Flavourings, Processing Aids and Materials in Contact with Food. EFSA J 2007. [DOI: 10.2903/j.efsa.2007.581] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
21
|
Kroger M, Meister K, Kava R. Low-calorie Sweeteners and Other Sugar Substitutes: A Review of the Safety Issues. Compr Rev Food Sci Food Saf 2006. [DOI: 10.1111/j.1541-4337.2006.tb00081.x] [Citation(s) in RCA: 239] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
22
|
Bookstaff RC, Stuard SB, Ward SR, Pesik PKM, Henwood SM. The safety of ethyl oleate is supported by a 91-day feeding study in rats. Regul Toxicol Pharmacol 2004; 39:202-13. [PMID: 15041149 DOI: 10.1016/j.yrtph.2004.01.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2003] [Indexed: 10/26/2022]
Abstract
The purpose of this study was to determine the safety of ethyl oleate (EO) in a 91-day feeding study in Sprague-Dawley rats. EO was mixed into AIN-93G purified diet at levels of 0, 3.3, 6.7, and 10% by weight (the high-dose males and females consumed 5.5 and 6.1g/kg/day EO, respectively). All diets were calorie- and fat-matched using high oleic safflower oil (HOSO) as the control fat. The study design followed the 1993 FDA draft "Redbook II" guidelines (Toxicological Principles for the Safety Assessment of Direct Food Additives and Color Additives Used in Food). There were 20 male and 20 female rats per group. EO in the diet was well tolerated and there were no toxicologically significant findings in any of the measured parameters (clinical observations, body weight gains, appearance of the feces, ophthalmic examinations, hematology, clinical chemistry, urinalysis, organ weights, histopathology, or male and female reproductive assessments). Mortality was limited to three males during the course of the study whose cause of death was unrelated to test material administration. The terminal body weight of the mid- and high-dose females was approximately 10% lower than that of the control group. This finding does not represent a toxicologically significant effect because rats on the EO diets gained more weight during the course of the study than historical control data on this strain of rats. The lower body weight relative to control rats is directly related to lower food consumption relative to the controls. The lower food consumption relative to controls is fully consistent with a decrease in the palatability of the EO-containing food versus the triglyceride-containing food. This conclusion is based on (1) a decrease in food consumption was noted within the first week (consistent with palatability preferences), (2) there was not a dose-response with regard to food consumption (mid-dose consumed less than high-dose), (3) the lack of cumulative decreases in food consumption which often are observed with toxicity, and (4) anecdotal experiences in our lab show that rats prefer diets containing high triglyceride fat over high EO-fat. Hepatocellular vacuolation typical of fat accumulation was noted for both control and high-dose animals. The incidence and severity of the vacuolation were higher for animals given 10% HOSO (controls) than for the animals given 10% EO. Serum calcium and phosphorous levels in high dose males were slightly, but statistically significantly, lower than in the controls. There was a dose-related increase in fecal fat concentration in both sexes from approximately 9% (control) to 18% in males, and from 4 (control) to 13% in females There were no visually obvious differences with regard to feces quality or quantity at any level of EO in the diet (i.e., color, diarrhea, weight, etc.). The increase in fat most likely represents small amounts of unabsorbed EO at the mid- and high-dose (estimates of EO absorption in this study are >80%). The No Observable Adverse Effect Level was determined to be 10% EO when administered daily in the diet for 91-days (approximately 6g EO/kg bw/day).
Collapse
Affiliation(s)
- Robert C Bookstaff
- The Procter and Gamble Company, Health Sciences Institute, Cincinnati, OH 45241, USA.
| | | | | | | | | |
Collapse
|
23
|
Mayhew DA, Comer CP, Stargel WW. Food consumption and body weight changes with neotame, a new sweetener with intense taste: differentiating effects of palatability from toxicity in dietary safety studies. Regul Toxicol Pharmacol 2004; 38:124-43. [PMID: 14550755 DOI: 10.1016/s0273-2300(03)00074-6] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Safety studies done with neotame, a sweetener with intense taste, demonstrate that changes in bodyweight (BW) and BW gain (BWG) are due to reduced food consumption (FC) rather than toxicity. When offered a choice, rats preferred basal diet to diet with relatively low concentrations of neotame. When no choice was available, rats ate less as concentrations increased, demonstrating reduced palatability. Changes in dietary concentrations of neotame resulted in changes in FC. The maximum tolerable doses (MTDs) in rats, dogs, and mice were due to decreases in BWG secondary to poor palatability of diets when neotame concentrations exceeded approximately 35,000 ppm. Concentrations were increased as animals grew to maintain constant dosing on a "mg/kg bw/day" basis. Food conversion efficiency (FCE) was not changed in rats during periods of active growth. The only consistent findings across safety studies were reductions in BW, BWG, and FC with no dose-response in rats, mice, and dogs. In definitive safety studies, there were no adverse findings related to neotame treatment from clinical observations, physical examinations, water consumption, or clinical pathology evaluations; nor was there morbidity, mortality, organ toxicity, macroscopic or microscopic postmortem findings. Analysis of data from long-term studies in Sprague-Dawley rats support the conclusion that changes in FC alone can cause the observed changes in BWG in neotame studies when changes are scaled allometrically [Regul. Toxicol. Pharmacol. (2003)]. Consequently, BW parameters are not appropriate endpoints for setting no-observed-effect levels (NOELs) for neotame.
Collapse
Affiliation(s)
- Dale A Mayhew
- Regulatory Affairs, The NutraSweet Company, 1801 Maple Street, Evanston, IL 60201, USA.
| | | | | |
Collapse
|